-
公开(公告)号:AU2006265932A1
公开(公告)日:2007-01-11
申请号:AU2006265932
申请日:2006-06-29
Applicant: ABBOTT LAB
Inventor: FUNG EMMA , HINTON PAUL R , LACY SUSAN E , ROGUSKA MICHAEL , KUMAR SHANKAR , DIXON RICHARD W , BELK JONATHAN P
IPC: C07K14/715
Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
-
公开(公告)号:ZA200901526B
公开(公告)日:2018-11-28
申请号:ZA200901526
申请日:2009-03-03
Applicant: ABBOTT LAB
Inventor: MELIM TERRY L , CUFF CAROLYN A , ARGIRIADI MARIA A , WU CHENGBIN , HINTON PAUL R , DIXON RICHARD W , KUMAR SHANKAR , BELK JONATHAN P , CHEN YAN , YING HUANG
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号:CA2662701C
公开(公告)日:2015-12-08
申请号:CA2662701
申请日:2007-09-07
Applicant: ABBOTT LAB
Inventor: WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
IPC: C07K16/24 , A61K39/395 , A61K47/48 , A61K49/00 , A61K51/10 , C07K16/46 , C12N15/13 , C12N15/63 , C12P21/08
Abstract: The present invention encompasses IL- 13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hlL-13 activity, e.g., in a human subject suffering from a disorder in which hTL-13 activity is detrimental.
-
公开(公告)号:NZ587766A
公开(公告)日:2013-06-28
申请号:NZ58776609
申请日:2009-03-03
Applicant: ABBOTT LAB
Inventor: HSIEH CHUNG-MING , BELK JONATHAN P , PEREZ JENNIFER M , BENATUIL LORENZO
Abstract: NZ 587766 Disclosed is a method of preparing a yeast library by electroporation of yeast cells, the method comprising the steps of: incubating the yeast cells in a solution comprising lithium acetate (LiAc) and dithiothreitol (DTT); providing a suspension comprising vector DNA, insert DNA, yeast cells, 0.1 to 10 M sorbitol, and 0.1 to 10 mM CaCl2 or MgCl2; and electroporating the suspension at 0.5kV/cm to greater than 12.5kV/cm with a capacitance of about 10 to about 50 mu ?F.
-
公开(公告)号:CR20130153A
公开(公告)日:2013-05-23
申请号:CR20130153
申请日:2013-04-03
Applicant: ABBOTT LAB
Inventor: LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
IPC: C07K16/00
Abstract: Proteínas de unión a IL-12 p40, en particular anticuerpos que se unen a la interleuquina-12 humana (hIL-12) y/o IL-23 humana (hIL-23). Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados.
-
公开(公告)号:CR20130150A
公开(公告)日:2013-05-23
申请号:CR20130150
申请日:2013-04-03
Applicant: ABBOTT LAB
Inventor: LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
IPC: C07K16/00
Abstract: Proteínas de unión a IL-12 p40, en particular anticuerpos que se unen a la interleuquina-12 humana (hIL-12) y/o IL-23 humana (hIL-23). Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados. Los anticuerpos preferidos tienen gran afinidad por hIL-12 y/o hIL-23 y neutralizan la actividad de hIL-12 y/o hIL-23 in vitro y in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa o una porción de unión al antígeno del mismo. También se provee un método de elaboración y un método de uso de los anticuerpos de la invención.
-
公开(公告)号:SG188846A1
公开(公告)日:2013-04-30
申请号:SG2013016084
申请日:2009-03-03
Applicant: ABBOTT LAB
Inventor: HSIEH CHUNG-MING , BELK JONATHAN P , PEREZ JENNIFER M , BENATUIL LORENZO
Abstract: Methods for Transforming Yeast AbstractThis invention is directed to the transformtion of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.Figure I
-
公开(公告)号:DOP2009000033A
公开(公告)日:2009-03-15
申请号:DO2009000033
申请日:2009-03-04
Applicant: ABBOTT LAB
Inventor: WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
Abstract: Proteínas de unión a !L-13. Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados. Los anticuerpos preferidos tienen gran afinidad por la hIL-13 y neutralizan la actividad de la hIL-13 in vitro e in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa o una porción de unión al antigeno del mismo. Tambien se provee un método de elaboración y un método de uso de los anticuerpos de la invención. Los anticuerpos, o porciones de anticuerpo, de la invención son de utilidad para detectar la hIL-13 y para inhibir la actividad hIL-13, por ejemplo, en un sujeto humano que sufre de un trastorno en el cual la actividad de la hIL-13 sea perjudicial.
-
公开(公告)号:BRPI0611714A2
公开(公告)日:2009-01-13
申请号:BRPI0611714
申请日:2006-06-29
Applicant: ABBOTT LAB
Inventor: LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
IPC: C07K14/715
Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
-
公开(公告)号:MXPA06011673A
公开(公告)日:2007-01-23
申请号:MXPA06011673
申请日:2005-04-08
Applicant: ABBOTT LAB
Inventor: REILLY EDWARD B , ROGUSKA MICHAEL , LACY SUSAN E , FUNG EMMA , BELK JONATHAN P
Abstract: La presente invencion se refiere a anticuerpos y sus porciones de union de antigeno que se unen a y activan un receptor de eritropoyetina. La invencion tambien se refiere a secuencias de acido nucleico que codifican dichos anticuerpos y porciones de union de antigeno. La presente invencion ademas se refiere a metodos para activar la actividad endogena de un receptor de eritropoyetina en un mamifero utilizando dichos anticuerpos y porciones de union de antigeno, metodos de tratamiento, asi como composiciones farmaceuticas que comprenden dichos anticuerpos y porciones de union de antigeno.
-
-
-
-
-
-
-
-
-